Get the Stockscreener App
72.25
0.63%
-0.47
Arcellx Inc stock is traded at $72.25, with a volume of 205.57K.
It is down -0.63% in the last 24 hours and up +13.42% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$72.72
Open:
$72.46
24h Volume:
205.57K
Relative Volume:
0.33
Market Cap:
$4.00B
Revenue:
$155.82M
Net Income/Loss:
$-40.42M
P/E Ratio:
-101.76
EPS:
-0.71
Net Cash Flow:
$3.58M
1W Performance:
+5.34%
1M Performance:
+13.42%
6M Performance:
-6.02%
1Y Performance:
+2.42%
1-Day Range:
$71.29
$73.69
1-Week Range:
$67.10
$74.66
52-Week Range:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
72.27 | 4.00B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.85 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.70 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.77 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
US Bancorp DE Has $462,000 Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ACLX June 20th Options Begin Trading - Nasdaq
Arcellx (NASDAQ:ACLX) Shares Gap Up – Time to Buy? - Defense World
Principal Financial Group Inc. Trims Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Myesha Lacy - IR Impact
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates - Simply Wall St
We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn - Yahoo Finance
New York State Common Retirement Fund Has $1.55 Million Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
HC Wainwright Predicts Arcellx’s Q1 Earnings (NASDAQ:ACLX) - Defense World
Optimistic Buy Rating for Arcellx Inc: Promising CAR-T Therapy and Strong Financial Position Highlighted - TipRanks
Arcellx Reports Promising 2024 Financial and Clinical Progress - MSN
Arcellx (NASDAQ:ACLX) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
State of New Jersey Common Pension Fund D Purchases New Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Why Arcellx Inc Stocks Are on the Rise - TipRanks
Arcellx Inc’s Anito-cel: Anticipated Market Leader with Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position - TipRanks
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating - TipRanks
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Rhumbline Advisers - Defense World
Rami Elghandour Sells 38,300 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - BioSpace
Arcellx earnings missed by $0.31, revenue fell short of estimates - Investing.com UK
Arcellx reports FY24 EPS ($2.00), consensus ($1.50) - TipRanks
Arcellx CEO Rami Elghandour sells $2.38 million in stock By Investing.com - Investing.com South Africa
Can Arcellx's 97% Response Rate in Multiple Myeloma Transform Treatment Landscape? - StockTitan
Arcellx CEO Rami Elghandour sells $2.38 million in stock - Investing.com
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - BioSpace
State of New Jersey Common Pension Fund D Buys Shares of 23,966 Arcellx, Inc. (NASDAQ:ACLX) - Defense World
arcellx director Kavita Patel sells $94,740 in common stock By Investing.com - Investing.com South Africa
Arcellx chief medical officer sells $647,772 in stock By Investing.com - Investing.com South Africa
arcellx director Kavita Patel sells $94,740 in common stock - Investing.com India
(ACLX) Investment Analysis and Advice - Stock Traders Daily
Allspring Global Investments Holdings LLC Sells 1,948 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx chief medical officer sells $647,772 in stock - Investing.com India
The Biotech Boom: Is Arcellx the Hidden Gem Investors Need? - Bit Perfect Solutions
The Untapped Potential of Biotech: Is Now the Time to Invest? - DSA
Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? - MSN
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Arcellx (ACLX) Expected to Announce Earnings on Wednesday - MarketBeat
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN
Is Arcellx (ACLX) Poised to Capture Significant Market Share? - MSN
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcellx Inc Stock (ACLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elghandour Rami | SEE REMARKS |
Feb 26 '25 |
Sale |
62.02 |
38,300 |
2,375,517 |
149,186 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):